Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 29:10:665.
doi: 10.3389/fimmu.2019.00665. eCollection 2019.

Immunopathogenesis of Behcet's Disease

Affiliations
Review

Immunopathogenesis of Behcet's Disease

Bainan Tong et al. Front Immunol. .

Abstract

Behcet's disease (BD) is a chronic systemic inflammatory vasculitis of unknown etiology characterized by recurrent episodes of oral aphthous ulcers, genital ulcers, skin lesions, ocular lesions, and other manifestations. Although the pathogenesis of BD is unclear, some studies have shown that immunological aberrations play an important role in the development and progression of BD. Infection-related trigger factors, including antigens and autoantigens, are believed to mediate the development of BD in patients with a genetic predisposition and subsequently activate the innate and adaptive immune systems, resulting in the production of numerous cytokines and chemokines to combat the infection-related factors. The study of the immunological mechanism of BD paves the way for the development of innovative therapies. Recently, novel biotherapy approaches, including interferon-α (IFN-α), tumor necrosis factor-α (TNF-α) antagonists, and other agents that target interleukins and their receptors, have shown promising results in the treatment of patients with refractory BD and have improved the prognosis of BD. In this review, we provide the current concepts of BD immunopathogenesis.

Keywords: Behcet's disease; autoimmune diseases; biotherapy/target therapies; cytokines; pathogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The role of innate immune cells in the pathogenesis of Behcet's disease.
Figure 2
Figure 2
The role of autoimmune T cells and cytokines in the pathogenesis of Behcet's disease.
Figure 3
Figure 3
The latest treatments of Behcet's disease is based on the immunopathogenesis of BD.

References

    1. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves O, et al. Behçet's disease—a contemporary review. J Autoimmun. (2009) 32:178–88. 10.1016/j.jaut.2009.02.011 - DOI - PubMed
    1. Deuter CM, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M. Behcet's disease: ocular effects and treatment. Prog Retinal Eye Res. (2008) 27:111–36. 10.1016/j.preteyeres.2007.09.002 - DOI - PubMed
    1. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet's disease. Autoimmun Rev. (2012) 11:687–98. 10.1016/j.autrev.2011.11.026 - DOI - PubMed
    1. Gul A, Ohno S. HLA-B*51 and Behçet disease. Ocular Immunol Inflamm. (2012) 20:37–43. 10.3109/09273948.2011.634978 - DOI - PubMed
    1. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. (2009) 61:1287–96. 10.1002/art.24642 - DOI - PMC - PubMed

Publication types

MeSH terms